Business focus
  • The company specialises in generic medicines, particularly niche generics – products with limited competition even after patent expiry.
  • EQL’s main markets are the Nordic countries (Sweden, Denmark, Norway, and Finland), with a growing presence in other parts of Europe.
  • The company does not produce in-house; instead, it relies on contract manufacturing through partners mainly in Europe and Asia, including India.
  • Its strategy is to identify generic drugs with small but stable markets, ensuring higher margins and less direct competition.
  • Financially, EQL has shown strong growth – for example, in its 2024/25 fiscal year, the company reported around 41% revenue growth compared to the previous period.

 

Operations and partnerships in India

EQL Pharma does not operate its own manufacturing facilities or sales offices in India. Instead, India plays a strategic partnership role in EQL’s supply and product development chain.

Business Sweden in India started a project with EQL Pharma, helping them with company registration. Shortly after that, Rupa had a meeting with CEO Axel Schörling and COO Martin Kristofersson in Bangalore to discuss EQL Pharma’s growing collaboration between its Swedish headquarters and Indian operations, which underscored the importance of effective cross-cultural understanding. Rupa then proposed a project with the objective for Business Sweden in India to assist EQL Pharma with a cross-cultural workshop to foster collaboration between their India team and Swedish headquarters.

iStock-531716249.jpg

GettyImages-1315389347.jpg

Key assessment areas to support EQL Pharma were:
  • Increase cultural awareness – for both teams in India and Sweden to understand social norms, values, and workplace expectations.
  • Promote empathy and collaboration – build a foundation for stronger interpersonal connections and mutual respect.
  • Improve communication – equip participants with practical tools to navigate cross-cultural interactions more effectively.
  • Support EQL Pharma’s global strategy – enable smoother day-to-day cooperation and align teams in both countries for long-term success.

The deliverables were two cultural workshops: the first for the India team in New Delhi on 28 August 2025 and the second for the Swedish and European teams in Croatia on 26 September 2025. Business Sweden was responsible for both developing the workshop material and conducting the sessions.